Efficacy and safety of ripertamab for treating primary membranous nephropathy among adults: a multicenter, retrospective, real-world study.

The observed trend of decreased 24-h UP in the initial therapy group was consistent with the trends observed in the total cohort, whereas the non-initial therapy group also showed a decreasing trend without statistical significance.

also in 47,180 other papers

While the serum creatinine levels decreased in all the groups, these changes did not reach statistical significance ( Figure 3D ). 3.4 Adverse events Ripertamab was well tolerated in almost all patients, with 9.6% (5/52) of patients reporting AEs.

also in 111,027 other papers